US FDA approves Semaglutide (Wegovy) for weight loss in non-diabetics to prevent heart attacks and stroke.
The US FDA has approved Semaglutide (Wegovy), an injectable weight loss drug, for non-diabetics who are overweight to prevent heart attacks and stroke. The approval is based on trials that showed weight loss with Semaglutide reduced cardiac mortality and morbidity by 20% and decreased cardiovascular death risk by 15% and death from any cause by 19% compared to a placebo. This development could help improve supply deficiencies and reduce exorbitant prices for existing medical weight loss options.
March 18, 2024
13 Articles